The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Abnormal intravascular leukocyte aggregation and clumping often seen in leukemia patients. The brain and lungs are the two most commonly affected organs. This acute syndrome requires aggressive cytoreductive modalities including chemotherapy and/or leukophoresis. It is differentiated from LEUKEMIC INFILTRATION which is a neoplastic process where leukemic cells invade organs.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
A transient increase in the number of leukocytes in a body fluid.
Progenitor cells from which all blood cells derive.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Measuring and weighing systems and processes.
Transplantation of an individual's own tissue from one site to another site.
A cell-separation technique where magnetizable microspheres or beads are first coated with monoclonal antibody, allowed to search and bind to target cells, and are then selectively removed when passed through a magnetic field. Among other applications, the technique is commonly used to remove tumor cells from the marrow (BONE MARROW PURGING) of patients who are to undergo autologous bone marrow transplantation.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
'Blood donors' are individuals who voluntarily and safely donate a specific amount of their own blood, which can be further separated into components, to be used for transfusion purposes or for manufacturing medical products, without receiving remuneration that is intended to reward them financially.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Process of using a rotating machine to generate centrifugal force to separate substances of different densities, remove moisture, or simulate gravitational effects. It employs a large motor-driven apparatus with a long arm, at the end of which human and animal subjects, biological specimens, or equipment can be revolved and rotated at various speeds to study gravitational effects. (From Websters, 10th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
A process of separating particulate matter from a fluid, such as air or a liquid, by passing the fluid carrier through a medium that will not pass the particulates. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
Proteins prepared by recombinant DNA technology.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Cell separation is the process of isolating and distinguishing specific cell types or individual cells from a heterogeneous mixture, often through the use of physical or biological techniques.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.

Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts. (1/386)

Cytokine-mobilized peripheral blood progenitor cells (PBPCs) have been used successfully for hematopoietic reconstitution following allogeneic transplantation. The ease of harvest, the faster engraftment and the high yield of CD34+ cells have made this source of hematopoietic progenitor cells (HPCs) an attractive alternative to bone marrow (BM). In the present study we compared the engraftment potential of conventional BM allografts and single leukapheresis products (LPs) collected from healthy donors following the administration of granulocyte colony-stimulating factor (G-CSF). For this, lineage-committed and primitive HPCs were assessed by flow cytometry and by colony- and cobblestone area-forming cell (CFC, CAFC) assays. Mean numbers of CD34+ cells in LPs (n = 11) were similar to that of BM grafts (n = 12) (278+/-57 vs 227+/-34 x 10(6) CD34+ cells). The frequencies of CFCs, week 5 CAFCs and week 8 CAFCs were 1.6-, 8.4- and 10.3-fold higher in the CD34+ compartment of mobilized blood than that of marrow, resulting in significantly higher yields of clonogenic HPCs in LPs when compared to BM grafts. We conclude that G-CSF preferentially mobilizes clonogenic progenitors capable of short- and, in particular, longterm reconstitution, and that the engraftment potential of single LPs is superior to that of BM allografts. Hence, the use of PBPCs may be favorable for protocols that include graft manipulations with expected cell loss (eg T cell depletion, CD34+ selection). PBPCs may also be advantageous for gene therapy trials due to their high numbers of potential target cells (eg CAFCs).  (+info)

Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. (2/386)

OBJECTIVE: To determine the efficacy and safety of filtration leukocytapheresis (LCP) for the treatment of rheumatoid arthritis (RA). METHODS: Twenty-five patients with drug-resistant RA were randomly assigned to undergo filtration LCP and 7 to undergo sham apheresis (control group) in a randomized, double-blind, placebo-controlled study. Three apheresis procedures were performed, with 1-week intervals between procedures. The efficacy of filtration LCP was evaluated according to the American College of Rheumatology definition of improvement in RA. Medications for each patient were unchanged for at least 6 months prior to enrollment and throughout the study. RESULTS: Tender joint counts, swollen joint counts, patient assessment of pain and global severity, physician assessment of global severity, and Health Assessment Questionnaire Disability Index were significantly improved in the LCP group compared with the control group (P < 0.05 for patient assessment of pain; P < 0.01 for all others). Seventy-nine percent of the patients in the LCP group exhibited significant overall improvement, while none of the patients in the control group were improved (P < 0.001). CONCLUSION: The results indicate that filtration LCP is an effective and well-tolerated treatment for patients with drug-resistant RA.  (+info)

Large-volume leukapheresis in pediatric patients: pre-apheresis peripheral blood CD34+ cell count predicts progenitor cell yield. (3/386)

BACKGROUND AND OBJECTIVE: In children it is very important to optimize PBPC harvesting and to reduce the number of leukaphereses per patient. The value of pre-apheresis peripheral blood CD34+ cell concentration as a predictor of PBPC yield was studied in 23 pediatric patients with hematologic and non-hematologic malignancies in order to optimize duration of PBPC collection. DESIGN AND METHODS: The patients underwent 25 stem-cell mobilization episodes with G-CSF alone and 40 large-volume leukapheresis procedures. Peripheral blood and harvested CD34+ cell concentrations were analyzed by means of flow cytometry. RESULTS: Using linear regression analysis, a highly significant correlation was found between the peripheral blood CD34+ cell count and the CD34+ cells/kg patient body weight collected on the apheresis day (r = 0.826, p = 0.0001). The results indicate that at least 1 x 10(6)/kg CD34+ cells can be harvested during one leukapheresis procedure in all patients if the pre-apheresis blood CD34+ cell count is > or = 30/microL and a CD34+ cell target of > or = 5 x 10(6)/kg is achieved in at least 80% of patients if this value is > or = 50 CD34+ cells/microL processing a median blood volume of 438.7 mL/kg (range, 207-560) over a median time of 232.5 minutes (range, 182-376). INTERPRETATION AND CONCLUSIONS: Our results suggest that the number of CD34+ cells harvested in a single large-volume leukapheresis can be predicted from the measurement of peripheral blood CD34+ cell concentration on the collection day.  (+info)

Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. (4/386)

BACKGROUND AND OBJECTIVE: Peripheral blood progenitor cells (PBPC) are now widely used to restore hematopoiesis following high dose chemotherapy in patients with malignancies. We sought to identify parameters that could predict the yield of PBPC after mobilization with chemotherapy (CT) with or without granulocyte colony-stimulating factor (G-CSF) in cancer patients. DESIGN AND METHODS: One hundred and fifty patients underwent 627 PBPC collections during the recovery phase following CT with (n = 469) or without (n = 142) G-CSF. Hemogram, CFC-assays and CD34+ cell count were performed on peripheral blood and leukaphereses products. After log transformation of the data, differences between groups were assessed with the unpaired t-test or one-way analysis of variance. RESULTS: Seventeen and two patients required 2 and 3 mobilization cycles respectively to reach our target of 15x10(4) CFU-GM/kg. In patients with lymphoma but not in those with leukemia, the yields of both CFU-GM and CD34+ cells/kg were dramatically increased when G-CSF was added to CT for mobilization. In collections primed with CT and G-CSF, better yields were obtained in patients with breast cancer or small-cell lung carcinoma (SCLC) as opposed to other solid tumors and leukemia. Among potential predictive factors of CT- and G-CSF-primed harvests, we found that the CD34+ cell count in peripheral blood (PB) was strongly correlated with both the CFU-GM and CD34+ cell yields. Except in leukemia patients, more than 1x10(6) CD34+ cells/kg were harvested when the CD34+ cell count in blood was above 20x10(6)/L. Similarly, better results were obtained in collections performed when the percentage of myeloid progenitors in blood on the day of apheresis was above 5 % or when the leukocyte count in blood was above 5x10(9)/L. INTERPRETATION AND CONCLUSIONS: A diagnosis of breast cancer or SCLC, a leukocyte count in PB of more than 5x10(9)/L, more than 5% myeloid progenitors or more than 20x10(6) CD34+ cells/L in PB were associated with higher yields of PBPC in collections mobilized with CT+G-CSF.  (+info)

A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. (5/386)

This randomized study compared the number of leukaphereses required to collect an optimal target yield of 5 x 10(6) CD34(+) peripheral blood progenitor cells/kg, using either stem cell factor (SCF) at 20 micrograms/kg/d in combination with Filgrastim at 10 micrograms/kg/d or Filgrastim alone at 10 micrograms/kg/d, from 203 patients with high-risk stage II, III, or IV breast cancer. Leukapheresis began on day 5 of cytokine administration and continued daily until the target yield of CD34(+) cells had been reached or a maximum of 5 leukaphereses performed. By day 5 of leukapheresis, 63% of the patients treated with SCF plus Filgrastim (n = 100) compared with 47% of those receiving Filgrastim alone (n = 103) reached the CD34(+) cell target yield. There was a clinically and statistically significant reduction (P <.05) in the number of leukaphereses required to reach the target yield for the patients receiving SCF plus Filgrastim (median, 4 leukaphereses) compared with patients receiving Filgrastim alone (median, 6 or more leukapherses; ie, <50% of patients reached the target in 5 leukaphereses). All patients receiving SCF were premedicated with antihistamines, albuterol, and pseudoephedrine. Treatment was safe, generally well tolerated, and not associated with life-threatening or fatal toxicity. In conclusion, SCF plus Filgrastim is a more effective peripheral blood progenitor cell (PBPC)-mobilization regimen than Filgrastim alone. In addition to the potential for reduced leukapheresis-related morbidity and costs, SCF offers additional options for obtaining cells for further graft manipulation.  (+info)

Surface phenotype analysis of CD16+ monocytes from leukapheresis collections for peripheral blood progenitors. (6/386)

In peripheral blood progenitor cell (PBPC) collections from patients with solid tumour or haematological malignancy, monocytes were separated into two subpopulations. The majority of monocytes expressed CD14 at a high density without CD16 antigen (the CD14+CD16- monocytes). The remaining monocytes co-expressed CD14 and CD16 (the CD14+CD16+ monocytes). These CD14+CD16+ monocytes amounted to 20.6 +/- 15.8%, while those in peripheral blood (PB) obtained from healthy volunteers were 7.3 +/- 3.1% (P < 0.05). When subdividing the CD14+CD16+ monocytes into CD14brightCD16dim and CD14dimCD16bright cells, both populations were found to be increased in PBPC collections. Since typical CD14+CD16+ monocytes are the CD14dimCD16bright population, we compared the additional surface antigens on CD14dimCD16bright monocytes with those of CD14+CD16- monocytes. In PBPC collections, the CD14dimCD16bright monocytes exhibited lower levels of CD11b, CD15, CD33 and CD38 expression and higher levels of CD4, CD11a, CD11c and MHC class II, and also revealed a higher percentage of CD4+ cells and a lower percentage of CD15+ cells and CD38+ cells, compared with the CD14+CD16- monocytes. When compared with the CD14dimCD16bright monocytes in PB, those in PBPC collections exhibited higher expression of CD4 and lower expression of CD11b, and also showed higher percentages of CD4+ cells and CD38+ cells and a lower percentage of CD11b+ cells. These results suggest that PBPC collections may be rich in the CD14+CD16+ monocytes in which the proportion of the immature population is increased. It is likely that these monocytes participate in the haematological and immune recovery after PBPC transplantation.  (+info)

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. (7/386)

An in vivo purging with intensive debulking chemotherapy prior to peripheral blood progenitor cell (PBPC) collection may reduce the risk of tumor contamination of the harvest products; however, it is usually associated with a marked reduction in PBPC mobilization. These issues have been considered while designing an adapted version of the high-dose sequential regimen for patients with lymphoid malignancies and bone marrow involvement. To reduce tumor contamination risks, PBPC collection was postponed to the end of the high-dose phase; however, in order to enhance progenitor cell mobilization, a chemotherapy-free lag period was introduced prior to the final mobilizing course. Thirty-nine patients (median age 47 years, range 26-62) with previously untreated indolent lymphoma entered this pilot study; all had advanced-stage disease, and 29 had overt marrow involvement. Sufficient numbers of PBPC to perform autograft with safety were harvested in 34 patients, with a median of 3 (range 2-5) leukaphereses. A median of 14.8 x 10(6) (range 2-51) CD34+/kg and 32.6 x 10(4) (range 1.77-250) colony forming units-granulocyte/macrophage/kg were collected per patient. In univariate analysis, the duration of the chemotherapy-free interval prior to the final mobilizing course, i.e. > or <65 days, was the most significant variable influencing progenitor mobilization. These data suggest that extensive in vivo tumor debulking is feasible provided that a sufficient chemotherapy-free period preceding the mobilizing course is allowed in order to allow a full recovery of marrow functions.  (+info)

Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases. (8/386)

The aim of the study was to evaluate peripheral blood progenitor cell mobilization by disease-specific chemotherapy in heavily pretreated patients with germ cell tumor (GCT), scheduled for high-dose chemotherapy. Thirty-four consecutive patients, 29 males and five females, with advanced GCT referred to our department for high-dose chemotherapy were evaluated retrospectively. Sixteen patients were mobilized by vinblastine 0.11 mg/kg on days 1 and 2, ifosfamide 1200 mg/m2 days 1-5 and cisplatin 20 mg/m2 days 1-5 (VeIP). In 10 patients, etoposide 75 mg/m2 days 1-5 was used instead of vinblastine (VIP), while in eight patients the mobilization was attempted by administering 7 g/m2 of cyclophosphamide. The choice of either etoposide or vinblastine was predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. Cyclophosphamide was selected in patients refractory to previous cisplatin-based salvage chemotherapy. Twenty-five out of 34 patients underwent a successful PBPC collection. In 17 of them one leukapheresis procedure was sufficient to collect the target number of CD34+ cells, while in eight patients a double procedure was necessary. Altogether 33 aphereses were performed in 25 patients. In nine patients leukapheresis was not attempted. This was due to the fact that the chemotherapy failed to mobilize the target number of CD34+ cells in eight of them, treated with the VeIP mobilizing regimen, while one patient treated with high-dose cyclophosphamide rapidly progressed during therapy and for this reason leukapheresis was not undertaken. In conclusion, in heavily pretreated patients with GCT, PBPC mobilization is feasible by a further course of salvage chemotherapy. The choice of either etoposide (VIP) or vinblastine (VeIP) can be predicated upon which of these two drugs was associated with best results during premobilization chemotherapy. In our hands, VeIP seems to be less satisfactory as mobilizing treatment than VIP, possibly due to a superior number of premobilization courses of chemo therapy in some patients. Moreover, high-dose cyclophosphamide remains a good alternative for mobilizing patients refractory to salvage chemotherapy.  (+info)

Leukapheresis is a medical procedure that involves the separation and removal of white blood cells (leukocytes) from the blood. It is performed using a specialized machine called an apheresis instrument, which removes the desired component (in this case, leukocytes) and returns the remaining components (red blood cells, platelets, and plasma) back to the donor or patient. This procedure is often used in the treatment of certain blood disorders, such as leukemia and lymphoma, where high white blood cell counts can cause complications. It may also be used to collect stem cells for transplantation purposes. Leukapheresis is generally a safe procedure with minimal side effects, although it may cause temporary discomfort or bruising at the site of needle insertion.

Hematopoietic Stem Cell Mobilization is the process of mobilizing hematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood. HSCs are immature cells that have the ability to differentiate into all types of blood cells, including red and white blood cells and platelets.

Mobilization is often achieved through the use of medications such as granulocyte-colony stimulating factor (G-CSF) or plerixafor, which stimulate the release of HSCs from the bone marrow into the peripheral blood. This allows for the collection of HSCs from the peripheral blood through a procedure called apheresis.

Mobilized HSCs can be used in stem cell transplantation procedures to reconstitute a patient's hematopoietic system after high-dose chemotherapy or radiation therapy. It is an important process in the field of regenerative medicine and has been used to treat various diseases such as leukemia, lymphoma, and sickle cell disease.

Leukostasis is not a formal medical diagnosis, but rather a complication that can occur in certain medical conditions. It's often used in the context of leukemia, where there is a rapid accumulation of white blood cells (leukocytes) in the small blood vessels, leading to impaired circulation, particularly in the lungs and brain. This can result in symptoms such as shortness of breath, cough, chest pain, headache, altered mental status, or even stroke. It's a medical emergency that requires immediate treatment, often involving leukopheresis (a procedure to remove white blood cells from the blood) and chemotherapy.

Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that specifically stimulates the production and survival of granulocytes, a type of white blood cell crucial for fighting off infections. G-CSF works by promoting the proliferation and differentiation of hematopoietic stem cells into mature granulocytes, primarily neutrophils, in the bone marrow.

Recombinant forms of G-CSF are used clinically as a medication to boost white blood cell production in patients undergoing chemotherapy or radiation therapy for cancer, those with congenital neutropenia, and those who have had a bone marrow transplant. By increasing the number of circulating neutrophils, G-CSF helps reduce the risk of severe infections during periods of intense immune suppression.

Examples of recombinant G-CSF medications include filgrastim (Neupogen), pegfilgrastim (Neulasta), and lipegfilgrastim (Lonquex).

CD34 is a type of antigen that is found on the surface of certain cells in the human body. Specifically, CD34 antigens are present on hematopoietic stem cells, which are immature cells that can develop into different types of blood cells. These stem cells are found in the bone marrow and are responsible for producing red blood cells, white blood cells, and platelets.

CD34 antigens are a type of cell surface marker that is used in medical research and clinical settings to identify and isolate hematopoietic stem cells. They are also used in the development of stem cell therapies and transplantation procedures. CD34 antigens can be detected using various laboratory techniques, such as flow cytometry or immunohistochemistry.

It's important to note that while CD34 is a useful marker for identifying hematopoietic stem cells, it is not exclusive to these cells and can also be found on other cell types, such as endothelial cells that line blood vessels. Therefore, additional markers are often used in combination with CD34 to more specifically identify and isolate hematopoietic stem cells.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

Plasmapheresis is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies or toxins, is then removed and replaced with fresh plasma or a plasma substitute. The remaining blood cells are mixed with the new plasma and returned to the body. This process is also known as therapeutic plasma exchange (TPE). It's used to treat various medical conditions including certain autoimmune diseases, poisonings, and neurological disorders.

Leukocytosis is a condition characterized by an increased number of leukocytes (white blood cells) in the peripheral blood. A normal white blood cell count ranges from 4,500 to 11,000 cells per microliter of blood in adults. Leukocytosis is typically considered present when the white blood cell count exceeds 11,000 cells/µL. However, the definition might vary slightly depending on the laboratory and clinical context.

Leukocytosis can be a response to various underlying conditions, including bacterial or viral infections, inflammation, tissue damage, leukemia, and other hematological disorders. It is essential to investigate the cause of leukocytosis through further diagnostic tests, such as blood smears, differential counts, and additional laboratory and imaging studies, to guide appropriate treatment.

Hematopoietic stem cells (HSCs) are immature, self-renewing cells that give rise to all the mature blood and immune cells in the body. They are capable of both producing more hematopoietic stem cells (self-renewal) and differentiating into early progenitor cells that eventually develop into red blood cells, white blood cells, and platelets. HSCs are found in the bone marrow, umbilical cord blood, and peripheral blood. They have the ability to repair damaged tissues and offer significant therapeutic potential for treating various diseases, including hematological disorders, genetic diseases, and cancer.

Hematopoietic Stem Cell Transplantation (HSCT) is a medical procedure where hematopoietic stem cells (immature cells that give rise to all blood cell types) are transplanted into a patient. This procedure is often used to treat various malignant and non-malignant disorders affecting the hematopoietic system, such as leukemias, lymphomas, multiple myeloma, aplastic anemia, inherited immune deficiency diseases, and certain genetic metabolic disorders.

The transplantation can be autologous (using the patient's own stem cells), allogeneic (using stem cells from a genetically matched donor, usually a sibling or unrelated volunteer), or syngeneic (using stem cells from an identical twin).

The process involves collecting hematopoietic stem cells, most commonly from the peripheral blood or bone marrow. The collected cells are then infused into the patient after the recipient's own hematopoietic system has been ablated (or destroyed) using high-dose chemotherapy and/or radiation therapy. This allows the donor's stem cells to engraft, reconstitute, and restore the patient's hematopoietic system.

HSCT is a complex and potentially risky procedure with various complications, including graft-versus-host disease, infections, and organ damage. However, it offers the potential for cure or long-term remission in many patients with otherwise fatal diseases.

I'm sorry for any confusion, but "Weights and Measures" is not a term that has a specific medical definition. It is a term used in various fields, including science, engineering, and commerce, to refer to systems and standards used to measure weight, length, volume, and other physical quantities.

However, if you're asking about the use of weights and measures in a medical context, it might refer to the standardized units of measurement used to quantify various aspects of health, disease, and treatment. For example:

* Weight: Measured in kilograms (kg) or pounds (lb), this is a measure of a person's mass.
* Height: Measured in meters (m) or feet/inches (ft/in), this is a measure of a person's height.
* Blood pressure: Measured in millimeters of mercury (mmHg), this is a measure of the force exerted by blood on the walls of the arteries.
* Temperature: Measured in degrees Celsius (°C) or Fahrenheit (°F), this is a measure of body temperature.
* Laboratory values: Various substances in the body, such as glucose or cholesterol, are measured in standardized units, such as millimoles per liter (mmol/L) or milligrams per deciliter (mg/dL).

These measurements help healthcare professionals assess a person's health status, diagnose medical conditions, and monitor the effects of treatment.

Autologous transplantation is a medical procedure where cells, tissues, or organs are removed from a person, stored and then returned back to the same individual at a later time. This is different from allogeneic transplantation where the tissue or organ is obtained from another donor. The term "autologous" is derived from the Greek words "auto" meaning self and "logos" meaning study.

In autologous transplantation, the patient's own cells or tissues are used to replace or repair damaged or diseased ones. This reduces the risk of rejection and eliminates the need for immunosuppressive drugs, which are required in allogeneic transplants to prevent the body from attacking the foreign tissue.

Examples of autologous transplantation include:

* Autologous bone marrow or stem cell transplantation, where stem cells are removed from the patient's blood or bone marrow, stored and then reinfused back into the same individual after high-dose chemotherapy or radiation therapy to treat cancer.
* Autologous skin grafting, where a piece of skin is taken from one part of the body and transplanted to another area on the same person.
* Autologous chondrocyte implantation, where cartilage cells are harvested from the patient's own knee, cultured in a laboratory and then implanted back into the knee to repair damaged cartilage.

Immunomagnetic separation (IMS) is a medical diagnostic technique that combines the specificity of antibodies with the magnetic properties of nanoparticles to isolate and concentrate target cells or molecules from a sample. This method is widely used in research and clinical laboratories for the detection and analysis of various biological components, including bacteria, viruses, parasites, and tumor cells.

The process involves the use of magnetic beads coated with specific antibodies that bind to the target cells or molecules. Once bound, an external magnetic field is applied to separate the labeled cells or molecules from the unbound components in the sample. The isolated targets can then be washed, concentrated, and further analyzed using various methods such as polymerase chain reaction (PCR), flow cytometry, or microscopy.

IMS offers several advantages over traditional separation techniques, including high specificity, gentle handling of cells, minimal sample manipulation, and the ability to process large volumes of samples. These features make IMS a valuable tool in various fields, such as immunology, microbiology, hematology, oncology, and molecular biology.

A leukocyte count, also known as a white blood cell (WBC) count, is a laboratory test that measures the number of leukocytes in a sample of blood. Leukocytes are a vital part of the body's immune system and help fight infection and inflammation. A high or low leukocyte count may indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder. The normal range for a leukocyte count in adults is typically between 4,500 and 11,000 cells per microliter (mcL) of blood. However, the normal range can vary slightly depending on the laboratory and the individual's age and sex.

A blood donor is a person who voluntarily gives their own blood or blood components to be used for the benefit of another person in need. The blood donation process involves collecting the donor's blood, testing it for infectious diseases, and then storing it until it is needed by a patient. There are several types of blood donations, including:

1. Whole blood donation: This is the most common type of blood donation, where a donor gives one unit (about 450-500 milliliters) of whole blood. The blood is then separated into its components (red cells, plasma, and platelets) for transfusion to patients with different needs.
2. Double red cell donation: In this type of donation, the donor's blood is collected using a special machine that separates two units of red cells from the whole blood. The remaining plasma and platelets are returned to the donor during the donation process. This type of donation can be done every 112 days.
3. Platelet donation: A donor's blood is collected using a special machine that separates platelets from the whole blood. The red cells and plasma are then returned to the donor during the donation process. This type of donation can be done every seven days, up to 24 times a year.
4. Plasma donation: A donor's blood is collected using a special machine that separates plasma from the whole blood. The red cells and platelets are then returned to the donor during the donation process. This type of donation can be done every 28 days, up to 13 times a year.

Blood donors must meet certain eligibility criteria, such as being in good health, aged between 18 and 65 (in some countries, the upper age limit may vary), and weighing over 50 kg (110 lbs). Donors are also required to answer medical questionnaires and undergo a mini-physical examination before each donation. The frequency of blood donations varies depending on the type of donation and the donor's health status.

Bone marrow purging is a procedure that involves the removal of cancerous or damaged cells from bone marrow before it is transplanted into a patient. This process is often used in the treatment of blood cancers such as leukemia and lymphoma, as well as other diseases that affect the bone marrow.

The purging process typically involves collecting bone marrow from the patient or a donor, then treating it with chemicals or medications to eliminate any cancerous or damaged cells. The purged bone marrow is then transplanted back into the patient's body, where it can help to produce healthy new blood cells.

There are several methods that can be used for bone marrow purging, including physical separation techniques, chemical treatments, and immunological approaches using antibodies or other immune system components. The choice of method depends on several factors, including the type and stage of the disease being treated, as well as the patient's individual medical history and condition.

It is important to note that bone marrow purging is a complex procedure that carries some risks and potential complications, such as damage to healthy cells, delayed recovery, and increased risk of infection. As with any medical treatment, it should be carefully evaluated and discussed with a healthcare provider to determine whether it is appropriate for a given patient's situation.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Blood component removal, also known as blood component therapy or apheresis, is a medical procedure that involves separating and removing specific components of the blood, such as red blood cells, white blood cells, platelets, or plasma, while returning the remaining components back to the donor or patient. This process can be used for therapeutic purposes, such as in the treatment of certain diseases and conditions, or for donation, such as in the collection of blood products for transfusion. The specific method and equipment used to perform blood component removal may vary depending on the intended application and the particular component being removed.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Peripheral Blood Stem Cell Transplantation (PBSCT) is a medical procedure that involves the transplantation of stem cells, which are immature cells found in the bone marrow that can develop into different types of blood cells. In PBSCT, these stem cells are collected from the peripheral blood instead of directly from the bone marrow.

The process begins with mobilization, where a growth factor medication is given to the donor to stimulate the release of stem cells from the bone marrow into the peripheral blood. After several days, the donor's blood is then removed through a procedure called apheresis, where the stem cells are separated and collected while the remaining blood components are returned to the donor.

The collected stem cells are then infused into the recipient's bloodstream, where they migrate to the bone marrow and begin to repopulate, leading to the production of new blood cells. This procedure is often used as a treatment for various malignant and non-malignant disorders, such as leukemia, lymphoma, multiple myeloma, and aplastic anemia.

PBSCT offers several advantages over traditional bone marrow transplantation, including faster engraftment, lower risk of graft failure, and reduced procedure-related morbidity. However, it also has its own set of challenges, such as the potential for increased incidence of chronic graft-versus-host disease (GVHD) and the need for more stringent HLA matching between donor and recipient.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

Centrifugation is a laboratory technique that involves the use of a machine called a centrifuge to separate mixtures based on their differing densities or sizes. The mixture is placed in a rotor and spun at high speeds, causing the denser components to move away from the center of rotation and the less dense components to remain nearer the center. This separation allows for the recovery and analysis of specific particles, such as cells, viruses, or subcellular organelles, from complex mixtures.

The force exerted on the mixture during centrifugation is described in terms of relative centrifugal force (RCF) or g-force, which represents the number of times greater the acceleration due to centrifugation is than the acceleration due to gravity. The RCF is determined by the speed of rotation (revolutions per minute, or RPM), the radius of rotation, and the duration of centrifugation.

Centrifugation has numerous applications in various fields, including clinical laboratories, biochemistry, molecular biology, and virology. It is a fundamental technique for isolating and concentrating particles from solutions, enabling further analysis and characterization.

Thiotepa is an antineoplastic (cancer-fighting) drug. It belongs to a class of medications called alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing. Thiotepa is used in the treatment of various types of cancers, including breast, ovarian, and bladder cancer.

It may be administered intravenously (into a vein), intravesically (into the bladder), or intrathecally (into the spinal cord). The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, thiotepa can have significant side effects, including nausea, vomiting, hair loss, and a weakened immune system. It is important for patients to discuss these potential risks with their healthcare provider before starting treatment.

Blood cells are the formed elements in the blood, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes). These cells are produced in the bone marrow and play crucial roles in the body's functions. Red blood cells are responsible for carrying oxygen to tissues and carbon dioxide away from them, while white blood cells are part of the immune system and help defend against infection and disease. Platelets are cell fragments that are essential for normal blood clotting.

A platelet transfusion is the process of medically administering platelets, which are small blood cells that help your body form clots to stop bleeding. Platelet transfusions are often given to patients with low platelet counts or dysfunctional platelets due to various reasons such as chemotherapy, bone marrow transplantation, disseminated intravascular coagulation (DIC), and other medical conditions leading to increased consumption or destruction of platelets. This procedure helps to prevent or treat bleeding complications in these patients. It's important to note that platelet transfusions should be given under the supervision of a healthcare professional, taking into account the patient's clinical condition, platelet count, and potential risks associated with transfusion reactions.

A Colony-Forming Units (CFU) assay is a type of laboratory test used to measure the number of viable, or living, cells in a sample. It is commonly used to enumerate bacteria, yeast, and other microorganisms. The test involves placing a known volume of the sample onto a nutrient-agar plate, which provides a solid growth surface for the cells. The plate is then incubated under conditions that allow the cells to grow and form colonies. Each colony that forms on the plate represents a single viable cell from the original sample. By counting the number of colonies and multiplying by the known volume of the sample, the total number of viable cells in the sample can be calculated. This information is useful in a variety of applications, including monitoring microbial populations, assessing the effectiveness of disinfection procedures, and studying microbial growth and survival.

Filtration in the medical context refers to a process used in various medical treatments and procedures, where a substance is passed through a filter with the purpose of removing impurities or unwanted components. The filter can be made up of different materials such as paper, cloth, or synthetic membranes, and it works by trapping particles or molecules based on their size, shape, or charge.

For example, filtration is commonly used in kidney dialysis to remove waste products and excess fluids from the blood. In this case, the patient's blood is pumped through a special filter called a dialyzer, which separates waste products and excess fluids from the blood based on size differences between these substances and the blood cells. The clean blood is then returned to the patient's body.

Filtration is also used in other medical applications such as water purification, air filtration, and tissue engineering. In each case, the goal is to remove unwanted components or impurities from a substance, making it safer or more effective for use in medical treatments and procedures.

Circulating neoplastic cells (CNCs) are defined as malignant cancer cells that have detached from the primary tumor site and are found circulating in the peripheral blood. These cells have undergone genetic and epigenetic changes, leading to uncontrolled cell growth and division, and can form new tumors at distant sites in the body, a process known as metastasis.

The presence of CNCs has been shown to be a prognostic factor for poor outcomes in various types of cancer, including breast, colon, and prostate cancer. The detection and characterization of CNCs can provide valuable information about the tumor's biology, aggressiveness, and response to therapy, allowing for more personalized treatment approaches.

However, the detection of CNCs is challenging due to their rarity in the bloodstream, with only a few cells present among billions of normal blood cells. Therefore, highly sensitive methods such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing are used for their identification and quantification.

Stem Cell Factor (SCF), also known as Kit Ligand or Steel Factor, is a growth factor that plays a crucial role in the regulation of hematopoiesis, which is the process of producing various blood cells. It is a glycoprotein that binds to the c-Kit receptor found on hematopoietic stem cells and progenitor cells, promoting their survival, proliferation, and differentiation into mature blood cells.

SCF is involved in the development and function of several types of blood cells, including red blood cells, white blood cells, and platelets. It also plays a role in the maintenance and self-renewal of hematopoietic stem cells, which are essential for the continuous production of new blood cells throughout an individual's lifetime.

In addition to its role in hematopoiesis, SCF has been implicated in various other biological processes, such as melanogenesis, gametogenesis, and tissue repair and regeneration. Dysregulation of SCF signaling has been associated with several diseases, including certain types of cancer, bone marrow failure disorders, and autoimmune diseases.

Agranulocytosis is a medical condition characterized by an abnormally low concentration of granulocytes (a type of white blood cells) in the peripheral blood. Granulocytes, which include neutrophils, eosinophils, and basophils, play a crucial role in the body's defense against infections. A significant reduction in their numbers can make an individual highly susceptible to various bacterial and fungal infections.

The condition is typically defined as having fewer than 150 granulocytes per microliter of blood or less than 1% of the total white blood cell count. Symptoms of agranulocytosis may include fever, fatigue, sore throat, mouth ulcers, and susceptibility to infections. The condition can be caused by various factors, including certain medications, medical treatments (such as chemotherapy or radiation therapy), autoimmune disorders, and congenital conditions. Immediate medical attention is required for individuals diagnosed with agranulocytosis to prevent and treat potential infections and restore the normal granulocyte count.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

Melphalan is an antineoplastic agent, specifically an alkylating agent. It is used in the treatment of multiple myeloma and other types of cancer. The medical definition of Melphalan is:

A nitrogen mustard derivative that is used as an alkylating agent in the treatment of cancer, particularly multiple myeloma and ovarian cancer. Melphalan works by forming covalent bonds with DNA, resulting in cross-linking of the double helix and inhibition of DNA replication and transcription. This ultimately leads to cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing cells, such as cancer cells.

Melphalan is administered orally or intravenously, and its use is often accompanied by other anticancer therapies, such as radiation therapy or chemotherapy. Common side effects of Melphalan include nausea, vomiting, diarrhea, and bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia. Other potential side effects include hair loss, mucositis, and secondary malignancies.

It is important to note that Melphalan should be used under the close supervision of a healthcare professional, as it can cause serious adverse reactions if not administered correctly.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

Granulocytes are a type of white blood cell that plays a crucial role in the body's immune system. They are called granulocytes because they contain small granules in their cytoplasm, which are filled with various enzymes and proteins that help them fight off infections and destroy foreign substances.

There are three types of granulocytes: neutrophils, eosinophils, and basophils. Neutrophils are the most abundant type and are primarily responsible for fighting bacterial infections. Eosinophils play a role in defending against parasitic infections and regulating immune responses. Basophils are involved in inflammatory reactions and allergic responses.

Granulocytes are produced in the bone marrow and released into the bloodstream, where they circulate and patrol for any signs of infection or foreign substances. When they encounter a threat, they quickly move to the site of infection or injury and release their granules to destroy the invading organisms or substances.

Abnormal levels of granulocytes in the blood can indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder.

Ifosfamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. Ifosfamide is used to treat various types of cancers, such as testicular cancer, small cell lung cancer, ovarian cancer, cervical cancer, and certain types of sarcomas.

The medical definition of Ifosfamide is:

Ifosfamide is a synthetic antineoplastic agent, an oxazaphosphorine derivative, with the chemical formula C6H15Cl2N2O2P. It is used in the treatment of various malignancies, including germ cell tumors, sarcomas, lymphomas, and testicular cancer. The drug is administered intravenously and exerts its cytotoxic effects through the alkylation and cross-linking of DNA, leading to the inhibition of DNA replication and transcription. Ifosfamide can cause significant myelosuppression and has been associated with urotoxicity, neurotoxicity, and secondary malignancies. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It involves the abnormal growth and proliferation of malignant lymphocytes (a type of white blood cell), leading to the formation of tumors in lymph nodes, spleen, bone marrow, or other organs. NHL can be further classified into various subtypes based on the specific type of lymphocyte involved and its characteristics.

The symptoms of Non-Hodgkin lymphoma may include:

* Painless swelling of lymph nodes in the neck, armpits, or groin
* Persistent fatigue
* Unexplained weight loss
* Fever
* Night sweats
* Itchy skin

The exact cause of Non-Hodgkin lymphoma is not well understood, but it has been associated with certain risk factors such as age (most common in people over 60), exposure to certain chemicals, immune system deficiencies, and infection with viruses like Epstein-Barr virus or HIV.

Treatment for Non-Hodgkin lymphoma depends on the stage and subtype of the disease, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up care is essential to monitor the progression of the disease and manage any potential long-term side effects of treatment.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Cell separation is a process used to separate and isolate specific cell types from a heterogeneous mixture of cells. This can be accomplished through various physical or biological methods, depending on the characteristics of the cells of interest. Some common techniques for cell separation include:

1. Density gradient centrifugation: In this method, a sample containing a mixture of cells is layered onto a density gradient medium and then centrifuged. The cells are separated based on their size, density, and sedimentation rate, with denser cells settling closer to the bottom of the tube and less dense cells remaining near the top.

2. Magnetic-activated cell sorting (MACS): This technique uses magnetic beads coated with antibodies that bind to specific cell surface markers. The labeled cells are then passed through a column placed in a magnetic field, which retains the magnetically labeled cells while allowing unlabeled cells to flow through.

3. Fluorescence-activated cell sorting (FACS): In this method, cells are stained with fluorochrome-conjugated antibodies that recognize specific cell surface or intracellular markers. The stained cells are then passed through a laser beam, which excites the fluorophores and allows for the detection and sorting of individual cells based on their fluorescence profile.

4. Filtration: This simple method relies on the physical size differences between cells to separate them. Cells can be passed through filters with pore sizes that allow smaller cells to pass through while retaining larger cells.

5. Enzymatic digestion: In some cases, cells can be separated by enzymatically dissociating tissues into single-cell suspensions and then using various separation techniques to isolate specific cell types.

These methods are widely used in research and clinical settings for applications such as isolating immune cells, stem cells, or tumor cells from biological samples.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

The word leukapheresis (/ˌluːkəfəˈriːsɪs/) uses combining forms of leuk- + apheresis, although it quite plausibly could be ... Leukapheresis is used in evolving CAR-T cell therapy to obtain leukocytes from a cancer patient or donor which can be modified ... Leukapheresis may be performed to decrease a very high white blood cell count, to obtain blood cells from a patient (autologous ... Leukapheresis (/ˌluˈkʌfɜːriːsɪs/ ) is a laboratory procedure in which white blood cells are separated from a sample of blood. ...
It may also be used to increase white blood cells for gathering during leukapheresis. It is given either by injection into a ... Filgrastim is used to treat neutropenia; acute myeloid leukemia; nonmyeloid malignancies; leukapheresis; congenital neutropenia ...
Leukapheresis - leukocytes (white blood cells). Leukopheresis is the removal of PMNs, basophils, eosinophils for transfusion ...
Ganzel, C; Becker, J; Mintz, PD; Lazarus, HM; Rowe, JM (May 2012). "Hyperleukocytosis, leukostasis and leukapheresis: practice ... and the less common leukapheresis procedure. This procedure is often utilized for asymptomatic hyperleukocytosis patients who ... It is an acute syndrome requiring aggressive cytoreductive modalities including chemotherapy and/or leukapheresis to both ...
ITH's research is primarily focused on its Tailored Leukapheresis (TLA) treatment for immune mediated inflammatory diseases ( ... IMIDs). Tailored Leukapheresis (TLA) treatment is an apheresis immunotherapy for selective removal of disease-causing pro- ... "Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis". Clinical Immunology. 149 (1): 73-82. doi ...
Steroid treatment and leukapheresis were later introduced, allowing granulocytes to be collected from healthy donors. However, ... Granulocytes are most often collected through leukapheresis, a process that separates the donor's white blood cells from their ... 297 The donor blood undergoes leukapheresis, a process by which white blood cells are separated from red blood cells and plasma ... 628 The white blood cell concentrate obtained through leukapheresis contains a high number of active T lymphocytes, which can ...
She was a Professor of Medicine, Chief of Supportive Therapy, and Chief of Leukapheresis at University of Texas MD Anderson ... She rose to the rank of professor and became Chief of Supportive Therapy and Chief of Leukapheresis service. Through the ...
With CVac this takes place outside the body of the patient (ex vivo), with dendritic cells obtained by leukapheresis. The ...
"Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer ...
... implication for filtration leukapheresis. J Clin Invest. 1977; 60:1183-1190. 37. Davies WA, Stossel TP. Peripheral hyaline ...
... precursors are isolated from the patient through leukapheresis and after maturation/stimulation of these precursors ex vivo, ... which involves obtaining antigen-presenting autologous dendritic cells from the patient following a leukapheresis procedure. ...
... effects for patients receiving photopheresis include hypotension and syncope resulting from volume shifts during leukapheresis ...
November 2001). "Use of pathology-specific peripheral blood CD34 thresholds to predict leukapheresis CD34 content with optimal ...
Of 74 participants who underwent leukapheresis (median age, 73 years), 61 (82%) received lisocabtagene maraleucel of whom 54% ( ...
Plasmapheresis may be used to decrease viscosity in the case of myeloma, whereas leukapheresis or phlebotomy may be employed in ...
... are extracted in a leukapheresis procedure. The blood product is sent to a production facility and incubated with a fusion ...
... is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis ...
... of ISLR in breast lipotransfer white adipose tissue CD34+ cells and significantly lower expression in leukapheresis CD34+ cells ...
Jeane Porter Hester, Professor of Medicine, Chief of Supportive Therapy, and Chief of Leukapheresis at University of Texas MD ...
... leukapheresis MeSH E02.120.285.790 - plateletpheresis MeSH E02.120.527.570 - leukapheresis MeSH E02.148.050.060 - angioplasty, ... leukapheresis MeSH E02.095.160.790 - plateletpheresis MeSH E02.095.520.400 - immunization MeSH E02.095.520.400.330 - ...
The treatment consists of removal of antigen-presenting cells from blood by leukapheresis and growing them with the fusion ...
... leukapheresis MeSH E05.200.500.363.285.790 - plateletpheresis MeSH E05.200.500.363.400 - immunomagnetic separation MeSH E05.200 ...
... and Chief of Leukapheresis at University of Texas MD Anderson Cancer Center Beverly Hoch 1975 Music - coloratura soprano and ...
... therapies rely involves injecting cancer patients with dendritic cells which have been harvested from them by leukapheresis (i. ...
... leukapheresis - leukemia - leukocyte - leukopenia - leukoplakia - leuprorelin - leuvectin - levamisole - levocarnitine - ...
Production of CAR-T cells involve removal of T cells via an extraction process known as leukapheresis, followed by cell culture ...
That study uses a whole-cell, CpG-activated, autologous tumor vaccine to induce anti-tumor immunity followed by leukapheresis ...
The word leukapheresis (/ˌluːkəfəˈriːsɪs/) uses combining forms of leuk- + apheresis, although it quite plausibly could be ... Leukapheresis is used in evolving CAR-T cell therapy to obtain leukocytes from a cancer patient or donor which can be modified ... Leukapheresis may be performed to decrease a very high white blood cell count, to obtain blood cells from a patient (autologous ... Leukapheresis (/ˌluˈkʌfɜːriːsɪs/ ) is a laboratory procedure in which white blood cells are separated from a sample of blood. ...
The global leukapheresis market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 ... The leukapheresis devices segment is projected to grow at the highest CAGR during 2023 to 2028. The growth of the leukapheresis ... TABLE 26 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION). TABLE 27 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, ... TABLE 233 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION. FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER ( ...
Learn about our leukapheresis process. With the wider use of cellular immune therapies, there is an increased demand from ... Leukapheresis is the process by which a large number of total nucleated cells are separated from the blood of a single donor, ...
Tags Global Leukapheresis Devices Market, Leukapheresis Devices, Leukapheresis Devices Market, Leukapheresis Devices Market ... Leukapheresis Devices The Leukapheresis Devices Market Is Estimated To Witness High Growth Owing To Rising Demand For CLL ... The Leukapheresis Devices Market is estimated to be valued at US$ 29.9 Mn in 2023 and is expected to exhibit a CAGR of 7.9% ... Demand, Leukapheresis Devices Market Growth, Leukapheresis Devices Market Share, medical devices Leave a comment ...
Ever heard of leukapheresis? This is a procedure that provides an opportunity to safely and selectively obtain large amounts of ... The IMMBASE study will collect leukapheresis samples at only one timepoint from 30 participants. In addition, there will be ... study which has been conducting leukapheresis to inform HIV cure strategies. The amazing participants for the IMMBASE study are ... the leukapheresis procedure will take place at Inkosi Albert Luthuli Central Hospital. ...
Donate through leukapheresis to advance cell-based therapies and save lives. ... LEUKAPHERESIS. Leukapheresis is different from a typical blood donation for money.. During your donation, a U.S. Food and Drug ... A leukapheresis donation is very safe, and our trained medical team is by your side every step of the way. ... By donating these cells through a process called leukapheresis, you help scientists across the US and abroad advance cell-based ...
Interpretation: Low frequency of differentiated CD3+CD27-CD28- T cells at leukapheresis represents a novel pre-infusion blood ... Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall ... Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall ... The significant association of low numbers of CD3+CD27-CD28- T cells in PB at the time of leukapheresis with CR at 3 months ...
What is the role of leukapheresis in the treatment of acute lymphoblastic leukemia (ALL)? ... patients should receive emergency leukapheresis to rapidly reduce the WBC count ...
Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy. Authors. Diego ... Results - Leukapheresis volume was reduced by almost fivefold (median: 185 to 40 mL), resulting in a higher product ... Key words: chimeric antigen receptor T cells, protocol, leukapheresis, high concentration, cryopreservation DOI: 10.2450/ ... Materials and methods - Sixty-eight processes of leukapheresis of 57 patients affected by refractory/relapsed B cell lymphoma ...
Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and ...
Timely Leukapheresis May Interfere with the « Fitness » of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL ...
Acute White Blood Cell Depletion (Leukapheresis): This therapy removes white blood cells from a patient with newly diagnosed or ...
Peripheral blood stem cell collection. Most donor stem cells are collected through a process called leukapheresis. ...
II is designed to isolate CD4+ cells from fresh or previously frozen peripheral blood mononuclear cells or washed leukapheresis ...
Leukapheresis Sometimes high numbers of CLL cells in your blood cause circulation problems. If this happens, a procedure called ... Leukapheresis Sometimes high numbers of CLL cells in your blood cause circulation problems. If this happens, a procedure called ... Leukapheresis for Chronic Lymphocytic Leukemia. American Cancer Society. May 10, 2018.. *Leukemia - Chronic Lymphocytic - CLL: ... leukapheresis, in which blood is removed from the body and processed through a machine that removes white blood cells and ...
Radiation to a single lesion within 14 days before leukapheresis;. *Radiation that includes a large bone marrow field such as ... Any other systemic therapy approved for the treatment of MM within 14 days before leukapheresis or within 14 days before ... Untreated or active infection at the time of initial Screening, at the time of leukapheresis, within 72 hours before ... Any experimental therapy within 8 weeks (for biologics) or 5 half-lives (for small molecules) before leukapheresis; ...
... with APC-conjugated antibodies from fresh or previously frozen peripheral blood mononuclear cells or washed leukapheresis ...
Timing of leukapheresis: one or two leukapheresis on days 5 and 6 are often sufficient. In other circumstances, additional ... one leukapheresis is often sufficient. In other circumstances, additional leukapheresis are recommended. ... Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 × 106 CD34+ cells/kg ... Leukapheresis should be performed during the period when the ANC rises from , 0.5 × 109/l to , 5.0 × 109/l. For patients who ...
... isolated by leukapheresis. PBMCs are cultured with PA2024, a fusion antigen composed of prostatic acid phosphatase (PAP) fused ...
Provenge Therapy - Dave Ligler during his first (out of 3) Leukapheresis , Source. ...
What is the role of leukapheresis in the treatment of acute lymphoblastic leukemia (ALL)? ... patients should receive emergency leukapheresis to rapidly reduce the WBC count ...
Patient has received any of the following treatments prior to leukapheresis: cytotoxic chemotherapy or radiation therapy within ... Patient received a live vaccine administration within 4 weeks prior to leukapheresis. ... or patients who have received any other form of immunosuppressive therapy within 7 days prior to leukapheresis. ... investigation treatment study or has participated in a study of an investigational agent within 4 weeks prior to leukapheresis. ...
Diagnostic LeukApheresis (DLA) is a standard clinical method that is frequently used to isolate mononuclear cells (MNCs) from ... To isolate CTCs from a leukapheresis product the white blood cells need to be depleted. For this purpose we will test multiple ...
o Leukapheresis. o Others. • Peripheral Blood Mononuclear Cells Market, By Source:. o Human. o Animals. • Peripheral Blood ... By Technique (Density Gradient Centrifugation, Leukapheresis, Others (Fluorescence Activated Cell Sorting, Magnetic-Activated ... Leukapheresis, Others (Fluorescence Activated Cell Sorting, Magnetic-Activated Cell Sorting, etc.). In terms of Source, the ...
White blood cells will be collected by a procedure called leukapheresis. Participants will be compensated for their efforts in ...
After screening, patients underwent leukapheresis. Bridging therapy was permitted during the manufacturing of the CAR T-cell ...
White blood cells will be collected by a procedure called leukapheresis. Participants will be compensated for their efforts in ...
In this process, T cells are collected from patients via leukapheresis and then re-engineered to express chimeric antigen ...
Each leukapheresis is followed by infusion of the personalized dose of Provenge within three days of the collection process. ... To prepare for the leukapheresis procedure, it is helpful to follow these tips:. *Drink more water than you normally do to stay ... Many men feel fatigued after leukapheresis.. How Provenge affects PSA. Doctors typically use the prostate-specific antigen (PSA ... To recap: A treatment course with Provenge involves three leukapheresis procedures, each of which is followed within 3 days by ...
  • After screening, patients underwent leukapheresis. (onclive.com)
  • In FELIX, patients underwent leukapheresis after screening and received bridging therapy during obe-cel manufacturing. (cancernetwork.com)
  • Leukapheresis (/ˌluˈkʌfɜːriːsɪs/ ) is a laboratory procedure in which white blood cells are separated from a sample of blood. (wikipedia.org)
  • Participant undergoing leukapheresis procedure. (ukzn.ac.za)
  • Working in partnership with highly experienced, trained South African National Blood Service (SANBS) staff and a medical doctor, the leukapheresis procedure will take place at Inkosi Albert Luthuli Central Hospital. (ukzn.ac.za)
  • White blood cells will be collected by a procedure called leukapheresis. (uab.edu)
  • The activated immune cells-your personalized Provenge dose-is given by infusion within about three days of the leukapheresis procedure. (prostate.net)
  • Leukapheresis - This procedure is done to collect large quantities of white blood cells. (healthengine.com.au)
  • PBMCs were isolated from leukapheresis products of healthy volunteers by density gradient centrifugation. (nih.gov)
  • Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft. (wikipedia.org)
  • Following enrollment and leukapheresis, patients could receive optional non-chemotherapy bridging, which could have included either corticosteroids or localized radiation. (cancernetwork.com)
  • To make your personalized dose, you must undergo a process called leukapheresis, which involves having your blood drawn either through a vein or through a central venous catheter placed into a large vein near the heart. (prostate.net)
  • Under this study, up to 10 patients with ALS will undergo leukapheresis. (houstonmethodist.org)
  • Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
  • Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
  • Materials and methods - Sixty-eight processes of leukapheresis of 57 patients affected by refractory/relapsed B cell lymphoma and 9 patients affected by acute lymphoblastic leukemia who were eligible for anti-CD19 CAR-T cell treatment performed between June 2019 and October 2022 were analyzed. (bloodtransfusion.it)
  • Timely Leukapheresis May Interfere with the « Fitness » of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients. (c3m-nice.fr)
  • 15 mg of prednisone daily or equivalent), or patients who have received any other form of immunosuppressive therapy within 7 days prior to leukapheresis. (moffitt.org)
  • In this process, T cells are collected from patients via leukapheresis and then re-engineered to express chimeric antigen receptors. (medscape.com)
  • To isolate CTCs from a leukapheresis product the white blood cells need to be depleted. (utwente.nl)
  • Leukapheresis is used in evolving CAR-T cell therapy to obtain leukocytes from a cancer patient or donor which can be modified and given to the patient as a therapeutic dose. (wikipedia.org)
  • Leukapheresis may be performed to decrease a very high white blood cell count, to obtain blood cells from a patient (autologous) or donor (allogeneic) for later transplant into the patient, or to obtain cells for research purposes. (wikipedia.org)
  • Leukapheresis is the process by which a large number of total nucleated cells are separated from the blood of a single donor, resulting in a high concentration of PBMC, such as lymphocytes (T cells, B cells, and NK cells), monocytes and dendritic cells. (bioscience.co.uk)
  • Most donor stem cells are collected through a process called leukapheresis. (medlineplus.gov)
  • citation needed] Leukapheresis may be performed to obtain the patient's own blood cells for a later transplant. (wikipedia.org)
  • Another novel use of cells obtained through leukapheresis is to stimulate a patient's immune system to target prostate cancer cells. (wikipedia.org)
  • Kymriah is manufactured by harvesting the patient's own T-cells using leukapheresis and engineering these cells to attack a specific target on leukemia cells, CD19. (childrensmercy.org)
  • Major complications associated with therapeutic leukapheresis procedures include pulmonary leukostasis, acute renal failure, and sometimes even death. (marketsandmarkets.com)
  • Therapeutic leukapheresis is associated with certain complications, such as those arising from a decreased WBC count and the possibility of adverse interactions with anticoagulation solutions. (marketsandmarkets.com)
  • The global leukapheresis market in terms of revenue was estimated to be worth $70 million in 2023 and is poised to reach $100 million by 2028, growing at a CAGR of 8.3% from 2023 to 2028. (marketsandmarkets.com)
  • The Leukapheresis Devices Market is estimated to be valued at US$ 29.9 Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. (makuv.com)
  • Patient received a live vaccine administration within 4 weeks prior to leukapheresis. (moffitt.org)
  • Patient is currently participating in another investigation treatment study or has participated in a study of an investigational agent within 4 weeks prior to leukapheresis. (moffitt.org)
  • Results - Leukapheresis volume was reduced by almost fivefold (median: 185 to 40 mL), resulting in a higher product concentration in one bag. (bloodtransfusion.it)
  • The IMMBASE study will collect leukapheresis samples at only one timepoint from 30 participants. (ukzn.ac.za)
  • cite journal}}: CS1 maint: multiple names: authors list (link) * National Institute for Health and Clinical Excellence, Leukapheresis for inflammatory bowel disease[permanent dead link] (guidance). (wikipedia.org)
  • Diagnostic LeukApheresis (DLA) is a standard clinical method that is frequently used to isolate mononuclear cells (MNCs) from blood for various applications. (utwente.nl)
  • By donating these cells through a process called leukapheresis , you help scientists across the US and abroad advance cell-based therapies to fight diseases, improve treatments, and save lives. (hemacenter.com)
  • Leukopaks are enriched leukapheresis products collected from peripheral blood and consist of various blood cells, including lymphocytes, monocytes, and dendritic cells. (marketsandmarkets.com)
  • The EasySep™ Release Human APC Positive Selection Kit is designed to isolate cells that are labeled with APC-conjugated antibodies from fresh or previously frozen peripheral blood mononuclear cells or washed leukapheresis samples by immunomagnetic positive selection. (stemcell.com)
  • A leukapheresis donation is very safe, and our trained medical team is by your side every step of the way. (hemacenter.com)
  • Their Tregs will subsequently be isolated and expanded from the leukapheresis product in the cGMP facility at Houston Methodist Hospital in order to develop and validate the Treg manufacturing process for the ultimate purpose of obtaining FDA approval in future trials. (houstonmethodist.org)
  • It is a sub-study within the Females Rising with Education, Support, and Health (FRESH) study which has been conducting leukapheresis to inform HIV cure strategies. (ukzn.ac.za)
  • This leukapheresis study proposes to continue our work in developing and optimizing our Treg manufacturing process. (houstonmethodist.org)
  • Hypocalcemia, decreased calcium levels also occurs in a large volume of leukapheresis procedures. (marketsandmarkets.com)
  • 6 months prior to leukapheresis and >3 months prior to lymphodepletion. (bcan.org)
  • 10. Subject is fit for leukapheresis and has adequate venous access for the cell collection. (bcan.org)
  • Additionally, biocompatible materials such as amphiphilic/zwitterionic polymers can also be explored as coating materials for use in leukapheresis membranes for enhanced hemocompatibility. (marketsandmarkets.com)